UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

Clinical pharmacology and therapeutics, 2007-05, Vol.81 (5), p.735-741

2007

Volltextzugriff (PDF)

PIV-based characterization of puffs in transitional pipe flow

Experiments in fluids, 2019-04, Vol.60 (4), p.1-17, Article 60

2019

Volltextzugriff (PDF)

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease

Journal of clinical pharmacy and therapeutics, 2009-10, Vol.34 (5), p.585-594

2009

Volltextzugriff (PDF)

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

Journal of thrombosis and haemostasis, 2007-12, Vol.5 (12), p.2429-2436

2007

Volltextzugriff (PDF)

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects

Current medical research and opinion, 2009-08, Vol.25 (8), p.1821-1829

2009

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease

Journal of clinical pharmacy and therapeutics, 2009-10, Vol.34 (5), p.575-583

2009

Volltextzugriff (PDF)

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

European heart journal, 2006-05, Vol.27 (10), p.1166-1173

2006

Volltextzugriff (PDF)

Birthplace and esophageal cancer incidence patterns among Asian‐Americans

Diseases of the esophagus, 2016-01, Vol.29 (1), p.99-104

2016

Volltextzugriff (PDF)

The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities

Journal of thrombosis and haemostasis, 2008-02, Vol.6 (2), p.359-365

2008

Volltextzugriff (PDF)

Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions

Circulation (New York, N.Y.), 1996-11, Vol.94 (9), p.2064-2071

1996

Volltextzugriff (PDF)

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

European heart journal, 2008, Vol.29 (1), p.21-30

2008

Volltextzugriff (PDF)

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

European heart journal, 2009-07, Vol.30 (14), p.1744-1752

2009

Volltextzugriff (PDF)

Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients

Journal of the American College of Cardiology, 2012-11, Vol.60 (20), p.2032-2040

2012

Volltextzugriff (PDF)

Acute Myocardial Infarction During Lung Volume Reduction Surgery

Anesthesia and analgesia, 1999-02, Vol.88 (2), p.332-334

1999

Volltextzugriff (PDF)

The active metabolite of prasugrel inhibits adenosine diphosphate‐ and collagen‐stimulated platelet procoagulant activities

Journal of thrombosis and haemostasis, 2008-02, Vol.6 (2), p.359-365

2008

Volltextzugriff (PDF)

The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease

Thrombosis and haemostasis, 2014, Vol.112 (3), p.589-597

2014

Volltextzugriff (PDF)

Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase

Circulation (New York, N.Y.), 1991-10, Vol.84 (4), p.1552-1560

1991

Volltextzugriff (PDF)

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

Journal of clinical pharmacology, 2008-04, Vol.48 (4), p.475-484

2008

Volltextzugriff (PDF)

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

Thrombosis and haemostasis, 2014, Vol.111 (5), p.943-950

2014

Volltextzugriff (PDF)

The nature of interactions between tissue-type plasminogen activator and platelets

Thrombosis research, 1990-07, Vol.59 (2), p.279-293

1990

Volltextzugriff (PDF)

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways

Thrombosis and haemostasis, 2013-12, Vol.110 (6), p.1223-1231

2013

Volltextzugriff (PDF)

Birthplace and esophageal cancer incidence patterns among Asian-Americans: Nativity and Asian-Am esophageal cancer

Diseases of the esophagus, 2016-01, Vol.29 (1), p.99-104

2016

Volltextzugriff (PDF)

Platelet Interactions With Fibronectin: Divalent Cation-Independent Platelet Adhesion to the Gelatin-Binding Domain of Fibronectin

Blood, 1993-04, Vol.81 (7), p.1778-1786

1993

Volltextzugriff (PDF)

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

British journal of clinical pharmacology, 2007-04, Vol.63 (4), p.421-430

2007

Volltextzugriff (PDF)

Absence of "rebound" platelet hyperreactivity following cessation of prasugrel

Thrombosis and haemostasis, 2011-07, Vol.106 (1), p.174-176

2011

Volltextzugriff (PDF)

1 – 25 von 1.242

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.016)
Mit Volltextzugriff
(1.053)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

PIV-based characterization of puffs in transitional pipe flow

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Birthplace and esophageal cancer incidence patterns among Asian‐Americans

The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities

Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients

Acute Myocardial Infarction During Lung Volume Reduction Surgery

The active metabolite of prasugrel inhibits adenosine diphosphate‐ and collagen‐stimulated platelet procoagulant activities

The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease

Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

The nature of interactions between tissue-type plasminogen activator and platelets

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways

Birthplace and esophageal cancer incidence patterns among Asian-Americans: Nativity and Asian-Am esophageal cancer

Platelet Interactions With Fibronectin: Divalent Cation-Independent Platelet Adhesion to the Gelatin-Binding Domain of Fibronectin

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

Absence of "rebound" platelet hyperreactivity following cessation of prasugrel

Suchergebnisse filtern